Aspire Biopharma Holdings (ASBP) EBT Margin (2025 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly EBT Margin of 11367.02% for Q1 2026, up 94.01% quarter-over-quarter from 189692.96% in Q4 2025.
Aspire Biopharma Holdings (ASBP) EBT Margin (2025 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported EBT Margin for 2 consecutive years, with 11367.02% the latest figure, recorded in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 12.09% |
| 10 | Aspire Biopharma Holdings | 8.34 Mn | -3.83 Mn | -30,086.00 | -2,009.61% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2,009.61% |
| Mar 31, 2026 | -11,367.02% |
| Dec 31, 2025 | -189,692.96% |
| Sep 30, 2025 | -135,268.16% |